Human VH Fragments from Transgenic Mice   Crescendo’s unique
transgenic mouse platform rapidly and predictably generates
high-affinity human heavy chain-only antibodies using the
natural process of in vivo B-cell development following
immunisation. VH single domain fragments from these heavy chain-
only antibodies require no humanisation, making this a rapid and
reliable route to candidate quality VH therapeutics.  VH
fragments are the smallest portions of immunoglobulin that
retain target specificity and potency and the most robust
antibody fragments in terms of stability, ease of engineering
and manufacture. This makes them highly attractive therapeutic
agents with significant advantages in the development of
products for local and topical delivery, pure antagonists and
bi- or multi-specifics.